RA Capital reveals next play in protein degradation, this time outside the cell

Healthcare

The first wave of biotechs developing drugs that employ targeted protein degradation target disease-causing proteins inside the cell. Biotech startup Avilar Therapeutics, formed by RA Capital Management and led by CEO Dan Grau, is targeting proteins outside of the cell and it’s out of stealth backed by $60 million.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.